Clinical Trial Update: DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing DB289 to trimethoprim-sulfamethoxazole for acute Pneumocystis jirovecii pneumonia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Pneumocystis Jirovecii Pneumonia

Drugs mentioned

• DB289
• Trimethoprim-sulfamethoxazole (trimethoprim-sulfamethoxazole)

Snippet

Sponsor: Immtech Pharmaceuticals, Inc | Conditions: Pneumonia, Interstitial Plasma Cell, Pneumocystis Carinii Pneumonia | Phase 3 | Status: TERMINATED